This study is looking at a new way to give medicine called surfactant to premature babies (born between 28 and 35 weeks) who have Respiratory Distress Syndrome (RDS). RDS makes it hard for babies to breathe. The study will compare two types of surfactant, Infasurf and Curosurf, given using a special method called MIST while the baby is on CPAP (a breathing support machine). We want to see if giving surfactant this way is as effective as other methods in reducing the number of babies who need a breathing tube (endotracheal intubation) within 7 days. Babies can join if they are less than 48 hours old, have RDS confirmed by X-ray, are on CPAP, and need at least 30% oxygen. Babies with birth defects or other causes for breathing problems cannot participate. The study is currently recruiting 262 infants.

Study design

This is a multi-center, randomized, controlled trial. It plans to enroll 262 preterm infants.

What's involved

If your baby participates, they will receive either Infasurf or Curosurf via MIST. A second dose may be given if needed. Management will mostly be at the discretion of the clinical team.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured at 7 days after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.